Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Am J Transplant. 2018 Nov 26;19(4):1129–1138. doi: 10.1111/ajt.15149

Figure 1.

Figure 1.

Monthly prevalence of highly sensitized candidates on the waitlist during the study period.

Post-KAS, cPRA 99.9%+ candidates represent the most common group of highly sensitized candidates on the waitlist. After an initial increase in the prevalence of highly sensitized candidates immediately after KAS, these candidates now represent a smaller proportion of the waitlist.

cPRA, calculated panel reactive antibody; D, December; M, March; J, June; S, September